Premium
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Author(s) -
Hansson Oskar,
Edelmayer Rebecca M.,
Boxer Adam L.,
Carrillo Maria C.,
Mielke Michelle M.,
Rabinovici Gil D.,
Salloway Stephen,
Sperling Reisa,
Zetterberg Henrik,
Teunissen Charlotte E.
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12756
Subject(s) - medicine , disease , clinical trial , positron emission tomography , alzheimer's disease , intensive care medicine , drug trial , pathological , neuroimaging , medical physics , pathology , psychiatry , radiology
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre‐)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease‐modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work‐up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand‐alone diagnostic AD markers, or before considering use in primary care.